A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia

Haematologica

Volumn 98, Issue 6, 2013, Pages 881-887

  Khellaf, Mehdi ^a   Viallard, Jean François ^b   Hamidou, Mohamed ^c   Cheze, Stéphane ^d   Roudot Thoraval, Françoise ^e   Lefrere, François ^f   Fain, Olivier ^g   Audia, Sylvain ^h   Abgrall, Jean François ⁱ   Michot, Jean Marie ^j   Dauriac, Charles ^k   Lefort, Sophie ^l   Gyan, Emmanuel ^m   Niault, Mathilde ^l   Durand, Jean Marc ⁿ   Languille, Laetitia ^a   Boutboul, David ^o   Bierling, Philippe ^a   Michel, Marc ^a   Godeau, Bertrand ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d Groupe Francophone des Myélodysplasies GFM   (France)

^e UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g HÔPITAL JEAN VERDIER   (France)

^h DIJON UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^j BICÊTRE HOSPITAL   (France)

^k RENNES UNIVERSITY HOSPITAL   (France)

^l Department of Hematology ^*  (France)

^m UNIVERSITY HOSPITAL OF TOURS   (France)

ⁿ HÔPITAL DE LA CONCEPTION   (France)

^o SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ELTROMBOPAG; RITUXIMAB; ROMIPLOSTIM;

ADULT; AGED; ARTHRALGIA; ARTICLE; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; BENZOATES; DRUG SUBSTITUTION; FEMALE; HUMANS; HYDRAZINES; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 84878428724     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.074633     Document Type: Article

References (28)

1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346 (13):995-1008.
2. Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol. 2006;133(4):364-74.
3. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3-40.
4. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-207.
5. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115(2):168-86.
6. Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc. 2004;79(4):504-22.
7. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1987;80(1):33-40.
8. Isaka Y, Kambayashi J, Kimura K, Matsumoto M, Uehara A, Hashikawa K, et al. Platelet production, clearance and distribution in patients with idiopathic thrombocytopenic purpura. Thromb Res. 1990;60 (2):121-31.
9. Louwes H, Zeinali Lathori OA, Vellenga E, de Wolf JT. Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am J Med. 1999;106(4):430-4.
10. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103(4):1364-9.
11. Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009;146(6):585-96.
12. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science. 1997;276(5319):1696-9.
13. Kuter DJ. New thrombopoietic growth factors. Blood. 2007;109(11):4607-16.
14. Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Landis AJ, Valoret EI, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009;27 (2):424-30.
15. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237-47.
16. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355 (16): 1672-81.
17. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161-71.
18. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377(9763):393-402.
19. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395-403.
20. Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia (ITP): the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012;120(5):960-9.
21. Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood. 2011;118(16): 4338-45.
22. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-93.
23. Cheng G. Eltrombopag for the treatment of immune thrombocytopenia. Expert Rev Hematol. 2011;4(3):261-9.
24. Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2011;363 (20):1889-99.
25. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76 (6):628-38.
26. Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109(11):4739-41.
27. Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 2012;367(1):11-9.
28. Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood. 2009;114(18): 3748-56.